Novartis
Novartis
Radiopharmaceuticals: Exciting Promise Tough Manufacturing Hurdles
🚀 Radiopharmaceuticals offer hope in cancer treatment, but their short shelf life poses unique manufacturing challenges. 🏭📦 Adaptation is key! 💊✨
Boosting Bioprocessing Efficiency with Perfused Models
🔬💡 Novartis scientists have developed a perfusion model to improve pre-stage bioprocessing efficiency, reducing culture medium consumption and experiment needs.
Novartis Boosts Portfolio with Monjuvi Acquisition
📰 Novartis acquires MorphoSys, gaining access to Monjuvi for lymphoma treatment. 🤝 Strengthens portfolio, expands biotech presence. 😊 Incyte benefits from collaboration agreement. 💼 Reflects global biotech growth.
Novartis Revolutionizes Cancer Therapy Production with Automation
📢 Novartis automates new radioligand therapy plant in Indianapolis! Increased supply and timely production for prostate cancer therapy. 👨🔬🤖🏭💉
Novartis Invests $100M to Revolutionize Cancer Therapy
📢 Novartis is investing $100 million in expanding radioligand production in Indianapolis, supporting targeted therapies for prostate cancer. 🏥 🎯 This investment will create 100 new jobs, as Novartis aims to become a leader in radioligand therapy production. 💼
Novartis Acquires Immunology Specialist in $425M Deal
📰 Novartis AG to buy immunology specialist Calypso Biotech BV for $425 million. 💉 Acquisition includes potential autoimmune treatment CALY-002. 🧪 Exciting developments in celiac disease and eosinophilic esophagitis research.
Novartis Sells French Biomanufacturing Facility to Seqens Transforming It into a Leading CDMO
💼 Novartis sells its biomanufacturing facility in France to Seqens, who plans to expand it into a CDMO. 💪🔬
